PER 2.67% 7.3¢ percheron therapeutics limited

Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-138

  1. 3,098 Posts.
    lightbulb Created with Sketch. 500
    The reality of our competitions mc is wildly different to some of these reports.

    I think its the trial failure possibility that scalps their forecasts down to the knees. Call me naive but im not factoring in failures.

    Was Wilsons the only one bold enough to project dollars in the sp if all goes well? I suspect their gigantic thorough report is better informed than these sub 50c 12month "targets".

    (agree uboy, didnt see ur comment before posting this)
    Last edited by RYNZN: 09/06/21
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.3¢
Change
-0.002(2.67%)
Mkt cap ! $65.81M
Open High Low Value Volume
7.3¢ 7.3¢ 7.2¢ $24.33K 334.2K

Buyers (Bids)

No. Vol. Price($)
2 83420 7.2¢
 

Sellers (Offers)

Price($) Vol. No.
7.3¢ 7464 3
View Market Depth
Last trade - 12.23pm 29/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.